{"result": "(\"entity\"<|>MELAS<|>EVENT<|>MELAS is a syndrome characterized by a range of neurological and metabolic symptoms, including migraines, hearing loss, and seizures, diagnosed in the patient in 2008.)\n##\n(\"entity\"<|>MUJER<|>PERSON<|>A 29-year-old woman admitted for repeated generalized seizures and a history of somnolence, nausea, vomiting, and constipation.)\n##\n(\"entity\"<|>MADRE<|>PERSON<|>The mother of the patient, who carries the A243G mutation and presents with diabetes mellitus, hearing loss, hyperprolactinemia, and grade 2 obesity.)\n##\n(\"entity\"<|>ARGININA<|>ORGANIZATION<|>Arginine is a chronic treatment administered to the patient, taken in a specific dosage every 12 hours.)\n##\n(\"entity\"<|>L-CARNITINA<|>ORGANIZATION<|>L-carnitine is a chronic treatment administered to the patient, taken in a specific dosage daily.)\n##\n(\"entity\"<|>COENZIMA Q10<|>ORGANIZATION<|>Coenzyme Q10 is a chronic treatment administered to the patient, taken in a specific dosage every eight hours.)\n##\n(\"entity\"<|>CLOPIDOGREL<|>ORGANIZATION<|>Clopidogrel is a chronic treatment administered to the patient, taken in a specific dosage every 24 hours.)\n##\n(\"entity\"<|>LACOSAMIDA<|>ORGANIZATION<|>Lacosamide is a chronic treatment administered to the patient, taken in a specific dosage every 12 hours.)\n##\n(\"entity\"<|>RANITIDINA<|>ORGANIZATION<|>Ranitidine is a chronic treatment administered to the patient, taken in a specific dosage every 12 hours.)\n##\n(\"entity\"<|>LEVETIRACETAM<|>ORGANIZATION<|>Levetiracetam is a chronic treatment administered to the patient, taken in a specific dosage every 12 hours.)\n##\n(\"entity\"<|>LAMOTRIGINA<|>ORGANIZATION<|>Lamotrigine is a chronic treatment administered to the patient, taken in a specific dosage every 12 hours.)\n##\n(\"entity\"<|>DOMPERIDONA<|>ORGANIZATION<|>Domperidone is a chronic treatment administered to the patient, taken in a specific dosage before each meal.)\n##\n(\"entity\"<|>LACTITOL<|>ORGANIZATION<|>Lactitol is a treatment administered to the patient for constipation.)\n##\n(\"relationship\"<|>MUJER<|>MELAS<|>The woman has been diagnosed with MELAS, which explains her neurological symptoms and medical history.<|>8)\n##\n(\"relationship\"<|>MUJER<|>MADRE<|>The woman is the daughter of the mother who carries the A243G mutation, which is relevant to her medical condition.<|>7)\n##\n(\"relationship\"<|>MUJER<|>ARGININA<|>Arginine is part of the chronic treatment regimen for the woman diagnosed with MELAS.<|>6)\n##\n(\"relationship\"<|>MUJER<|>L-CARNITINA<|>L-carnitine is part of the chronic treatment regimen for the woman diagnosed with MELAS.<|>6)\n##\n(\"relationship\"<|>MUJER<|>COENZIMA Q10<|>Coenzyme Q10 is part of the chronic treatment regimen for the woman diagnosed with MELAS.<|>6)\n##\n(\"relationship\"<|>MUJER<|>CLOPIDOGREL<|>Clopidogrel is part of the chronic treatment regimen for the woman diagnosed with MELAS.<|>6)\n##\n(\"relationship\"<|>MUJER<|>LACOSAMIDA<|>Lacosamide is part of the chronic treatment regimen for the woman diagnosed with MELAS.<|>6)\n##\n(\"relationship\"<|>MUJER<|>RANITIDINA<|>Ranitidine is part of the chronic treatment regimen for the woman diagnosed with MELAS.<|>6)\n##\n(\"relationship\"<|>MUJER<|>LEVETIRACETAM<|>Levetiracetam is part of the chronic treatment regimen for the woman diagnosed with MELAS.<|>6)\n##\n(\"relationship\"<|>MUJER<|>LAMOTRIGINA<|>Lamotrigine is part of the chronic treatment regimen for the woman diagnosed with MELAS.<|>6)\n##\n(\"relationship\"<|>MUJER<|>DOMPERIDONA<|>Domperidone is part of the chronic treatment regimen for the woman diagnosed with MELAS.<|>6)\n##\n(\"relationship\"<|>MUJER<|>LACTITOL<|>Lactitol is part of the treatment regimen for the woman diagnosed with MELAS, specifically for constipation.<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: de coenzima A17 .\n       • Creatina:    se metaboliza a fosfocreatina, un donante esencial de fosfato para\n       la regeneración de ATP en el músculo y en el cerebro, lo que mejora la fuerza\n       muscular en el ejercicio en el síndrome de MELAS27,28 .\n                                                                                              47\n---\n    Caso clínico\n             Mujer de 29 años de edad, ingresada por crisis convulsivas repetidas generalizadas,\n    e historia de somnolencia, náuseas, vómitos y estreñimiento.\n\n\n\n             Entre sus antecedentes destacaba un síndrome de MELAS diagnosticado en\n    2008 (mutación 3246A>G) con clínica heterogénea;\n         •   Neurológico: migrañas, hipoacusia neurosensorial, epilepsia parcial compleja\n         con generalización secundaria, miopatía, retraso psicomotor y lesiones bilaterales\n         parieto-temporal-occipitales tipo ictus-like con clínica fundamentalmente visual.\n         •   Endocrino: baja talla en la infancia, hiperprolactinemia sintomática y microade-\n         noma hipofisario de 3mm resuelto con tratamiento con bromocriptina desde 2006\n         a 2009, hipogonadismo hipogonadotropo persistente y bajo peso.\n         •   Digestivo: epigastralgia con estudio endoscópico compatible con gastritis\n         atrófica, pólipos múltiples y episodios recurrentes de nauseas, vómitos y altera-\n         ción del hábito intestinal que oscila entre diarrea y estreñimiento.\n\n\n\n             La paciente había tenido ingresos cada 6 meses desde 2006 por deterioro\n    neurológico y crisis epilépticas por mal cumplimiento del tratamiento debido a las\n    náuseas y vómitos.\n\n\n\n             Otros antecedentes familiares: madre portadora de la mutación A243G y como\n    manifestaciones presentaba DM, hipoacusia neurosensorial, hiperprolactinemia y\n    sobrepeso grado 2.\n\n\n\n             La situación basal de la paciente era de dependencia para actividades basales\n    de la vida diaria.\n\n\n\n             El tratamiento crónico consistía en arginina (1 sobre de 7 gramos diluido en 250\n    cc de agua cada 12 horas), L-carnitina (10 ml al día), coenzima Q10 (2 comprimidos de\n    50 mg cada ocho horas), clopidogrel (75 mg cada 24 horas), lacosamida (200 mg cada\n    12 horas), ranitidina (150 mg cada 12 horas), levetiracetam (1000 mg cada 12 horas),\n    lamotrigina (100 mg cada 12 horas), domperidona (10 ml antes de cada comida) y si\n    estreñimiento lactitol.\n\n\n\n             Otros datos de la historia clínica se pueden ver en las Tablas 2 y 3.\n\n\n\n48\n---\nTablas 2 y 3. Exploración física y pruebas complementarias al ingreso\n\n\n\n                 Glu 134 mg/dl (74-106)\n                  Urea 51 mg/dl (15-46)                     NRL: Somnolienta. Glasgow 9\n                      Cr 0.73 (0.5-1.1)                     Hipotonía generalizada. No\n                     Na 139 (132-146)                       asimetría facial. ROT: normales\n                       K 3.5 (3.5-5.5)                      excepto rotulianos y aquíleos.\n                           CPK 129                          Sensibilidad, coordinación y\n                       Mioglobina 74                        marcha no explorables.\n                           PCR 3.2                          Cardiorespiratorio: Rítmico y sin\n           Anormal y sedimentos: normal.                    soplos. MVC sin alteraciones.\n                       Metilcetona +.                       Abdomen: Blando y depresible\n                   Hb 15.6 gr/dl (12-16)                    ruidos intestinales aumentados. No\n                    Htco 31.2 % (36-46)                     defensa ni irritación peritoneal.\n             Leucocitos 29.18 (4.5-11*10 9)                 MMII: sin edemas. Pulsos pedios\n                     (N 95,2%, L2.4%)                       palpables y simétricos.\n                     Plaquetas 457000\n                            TP 1.2\n\n\n\n          En la valoración nutricional se recogieron los siguientes datos: peso habitual\n45 kg, peso actual 32 kg, talla 1,5 m IMC 14.2 kg/m2 La superficie corporal era de 1.185 m 2 .\nPresentaba una pérdida de peso progresiva de 18 kg desde antes del diagnóstico (2006)\ny asociada fundamentalmente a náuseas, vómitos y los ingresos. Desde la última\nrevisión en endocrinología, tres meses antes, había sufrido una pérdida de peso de 2 kg\n(5.\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}